You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023406049
Dec 2023160024
Jan 2024109011
Feb 20246009
Mar 2024142021
Apr 2024152014
May 2024120014
Jun 2024168023
Jul 2024164010
Aug 2024176014
Sep 2024172014
Oct 2024186040
Nov 2024286035
Dec 2024194048
Jan 2025141025
Feb 202576028
Mar 20250041
Apr 20250015
May 20250018
Jun 2025009
Total27120462